Cyclic nucleotide-gated channel alpha-1 (CNGA1) (CNGA1)

Cyclic nucleotide-gated channel alpha-1 (CNGA1) is a critical pore-forming subunit of the cyclic nucleotide-gated (CNG) ion channels located in the outer segments of retinal rod photoreceptors [4, 5]. These channels play a fundamental role in the visual phototransduction cascade by converting light-induced changes in intracellular cyclic guanosine monophosphate (cGMP) levels into electrical signals [5, 9]. In the dark, high levels of cGMP keep the CNGA1-containing channels open, allowing an influx of sodium and calcium ions that maintains the cell in a depolarized state [4, 10]. Upon light absorption, cGMP levels drop, causing the channels to close and the cell to hyperpolarize, which ultimately signals the presence of light to the brain [5, 9]. Mutations in the CNGA1 gene are a known cause of autosomal recessive retinitis pigmentosa (RP49), a degenerative eye disease characterized by night blindness and progressive loss of peripheral vision [7, 8]. Therapeutic strategies currently under investigation include gene augmentation therapies, such as VG901, which aim to deliver functional copies of the CNGA1 gene to the retina to restore channel activity and preserve vision [9, 13]. Additionally, the channel is sensitive to various pharmacological agents, including divalent cations and certain local anesthetics like tetracaine, which can block the pore and modulate its gating properties [10, 14].

Other names

CNCGCNCG1CNG1RCNC1RCNCaRP49Rod photoreceptor cGMP-gated cation channel subunit alphacGMP-gated cation channel alpha-1

Channel blocker, Gene augmentation